Endocrine Abstracts

Background: The impact of subclinical hyperthyroidism (sHT) on lipids concentration is still unclear. The aim of the study was to prospectively evaluate the changes in lipid profile in patients with sHT and following restoration of euthyroid state.Patients and methods: The studied group consisted of 44 patients (37 females, 7 males), diagnosed with endogenous sHT in the course of either toxic multinodular goiter, diffused thyroid autonomy or autonomously...

Background: Renal hyperparathyroidism (rHPT) may affect up to 30% of dialysispatients with end-stage renal disease (ESRD). rHPT is associated with an increased risk of cardiovascular events (CE) and bone diseases such as pain or renal osteodystrophy. Total or subtotal parathyroidectomy may be a chance to reduce the severity of the symptoms and decrease the risk of CE and death. Pre-operative scintigraphy and ultrasound diagnostics in rHPT may be insufficient at even up to 60% ...

Background: Carcinoid crisis (CC) may rarely occur as a complication of general anesthesia/surgery or peptide receptor radionuclide therapy (PRRT) in patients with neuroendocrine tumor (NET). The incidence of CC as a complication of PRRT is underestimated and comes to 10% of all radioisotope therapies. Progressive organ dysfunction, decrease or increase in blood pressure SBP <80 mmHg or >180 mmHg, unexplained tachyarrhythmia with heart rate >120/ min, bronchoconstr...

Background: Neuroendocrine neoplasms (NENs) are rare group of tumors with a different clinical course, prognosis and location. Radioligand therapy (RLT) is currently registered in gastroenteropancreatic (GEP) G1-G2 NENs. Tumors with an unknown point of origin, diagnosed outside the gastrointestinal tract and pancreas, or with Ki-67 >20%, do not qualify in many countries to standard RLT.Materials and Methods: 48 patients with progressive NENs of unkno...

Introduction: The good expression of somatostatin receptors in neuroendocrine tumor tissue enables effective treatment with peptide receptor radionuclide therapy (PRRT). To date, there is no clear consensus on the optimal PRRT arrangement due to the possibility of the use of different radiopharmaceutical regimens. In theory, the simultaneous use of two radionuclides (90Y and 177Lu) with different energy and radiation ranges should be more effective than monotherapy. The main o...

Aim/Introduction: Peptide Receptor Radionuclide Therapy (PRRT) is an effective treatment for disseminated neuroendocrine tumors (NETs) expressing somatostatin receptors. Despite many published studies, the consensus on the optimal PRRT treatment algorithm has not been reached yet. The main objective of the DUONEN multicenter, randomized, phase III study (EUDRACT No: 2020-006068-99) is the development of a dosimetry-based personalized PRRT algorithm. The second goal includes th...